Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

SEPTEMBER 23, 2022

Going forward, MAPS will focus on advocating for psychedelic policy reform to include state funding for public education, harm reduction, and unarmed crisis response services. On the heels of the update about SB 519 was news of Governor Gavin Newsom vetoing another proposed piece of drug policy legislation sponsored by Senator Wiener.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 10 × 10. See, e.g., Jennifer M. Mitchell et al., Divito & Robert F.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

MAY 29, 2022

FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. More recently, MDMA therapy has inched closer to FDA approval. Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JANUARY 19, 2022

With his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident Congressman Moran will be a great asset to IGC especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals that have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).

Therapy 89

Therapy Legalization Chronic Pain DEA 89

The Cannigma

AUGUST 31, 2021

A 2018 research paper in the International Journal of Drug Policy analyzed in-depth interviews carried out with 24 Israeli physicians working in pain medicine, oncology, and family medicine, and found that “physicians discussed contrasting narratives of cananbi, presenting it as both a medicine and non-medicine.”

Education 101

Education Clinical Trials Medicine Policy 101

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Framings that more often carried a negative tone were related to poor evidence and safety issues.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Amanda Feilding, Countess of Wemyss and March is an English drug policy reformer, lobbyist and research coordinator. Andrew Yang.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51